Mozambique Launches Groundbreaking HIV Prevention Injection Offering Over 99% Protection
Maputo, Mozambique — In a significant stride in the fight against HIV, Mozambique’s health authorities unveiled a revolutionary long-acting injectable PrEP (pre-exposure prophylaxis) on Wednesday. The new drug, lenacapavir, is administered just twice a year and boasts an efficacy rate of over 99% in preventing HIV infections.
Health Minister Ussene Isse announced the rollout during a ceremony in Matola, a municipality in southern Mozambique, calling the introduction of lenacapavir a “milestone” in the country’s efforts to curb the spread of HIV. “From today, Mozambique joins the ranks of pioneering nations offering an injectable solution that drastically reduces the risk of HIV transmission,” he declared.
Lenacapavir, designed for individuals aged 15 and above, works by inhibiting the replication of the HIV virus within the body. Unlike daily oral PrEP medications, which require consistent adherence, this injectable option simplifies prevention by requiring only two doses annually. Health officials believe this innovation will significantly improve accessibility and adherence, particularly among adolescents and young adults, who account for a disproportionate number of new infections.
According to Minister Isse, Mozambique recorded approximately 92,000 new HIV cases in 2024, with 15,000 occurring in adolescents aged 10 to 19. The introduction of lenacapavir expands the range of prevention tools available, offering citizens more effective and tailored options.
Gilion Michila, Matola’s district administrator, emphasized the transformative potential of the new drug. “This medicine opens new possibilities for protection, care, and hope,” she said. “We urge our communities to seek information, consult healthcare professionals, and share this knowledge with loved ones. Every informed decision has the power to save lives.”
The rollout follows lessons learned from Mozambique’s pilot program with injectable cabotegravir, launched in 2024 in the northern province of Nampula. Deputy National Director of Public Health Aleny Couto described lenacapavir as a critical addition to the country’s HIV prevention toolkit. “This injectable PrEP complements existing methods, strengthening our combined prevention strategy,” she explained.
Initially, lenacapavir will be available in phases across 55 health units in 15 districts of Zambézia province and in Maputo city and province. Mozambique joins neighboring countries such as Eswatini, Zambia, and Zimbabwe, which have already adopted this groundbreaking technology.
The launch marks a pivotal moment in Mozambique’s ongoing battle against HIV, offering renewed hope to millions. As the country continues to expand access to innovative prevention tools, officials remain committed to reducing new infections and improving public health outcomes.
— Reported by Nexio News
